Making methods rugged for regulated bioanalysis

Papers of special note have been highlighted as: • of interest

References

• 1 Nowatzke W, Rogers K, Wells E, Bowsher R, Ray C, Unger S. Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. Bioanalysis 3, (5) 509–521 (2011).
  CASGoogle Scholar
• 2 Ray CA, Patel V, Shih J et al. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. J. Pharm. Biomed. Anal. 49(2), 311–318 (2009).
  Medline CASGoogle Scholar
• 3 Wang J, Aubry A-F, Cornelius G et al. Importance of mobile phase and injection solvent selection during rapid method development and sample analysis in drug discovery bioanalysis illustrated using convenient multiplexed LC–MS/MS. Anal. Methods 2, 375–381 (2010).
  CASGoogle Scholar
• 4 High throughput bioanalytical sample preparation methods and automation strategies. Wells DA. Elsevier, Amsterdam, 236–484, (2003).
  Google Scholar
• 5 Svennberg H, Bergh S, Stenhoff H. Factorial design for the development of automated solid-phase extraction in the 96-well format for determination of tesaglitazar, in plasma, by liquid chromatography-mass spectrometry. J. Chromatogr. B. 787, 231–241 (2003).
  Medline CASGoogle Scholar
• 6 Janiszewski JS, Swyden MC, Fouda HG. High-throughput method development approaches for bioanalytical mass spectrometry. J. Chrom. Sci. 38, 255–258 (2000).
  Medline CASGoogle Scholar
• 7 Zhang N, Hoffman KL, Li W, Rossi DT. Semi-automated 96-well liquid-liquid extraction for quantitation of drugs in biological fluids. J. Pharm. Biomed. Anal. 22, 131–138 (2000).
  MedlineGoogle Scholar
• 8 Pfeffer M, Windt H. Automatization for development of HPLC methods. Fresenius J. Anal. Chem. 369(1), 36–41 (2001).
  Medline CASGoogle Scholar
• 9 Krisko RM, McLaughlin K, Koenigbauer MJ, Lunte CE. Application of a column selection system and DryLab software for high-performance liquid chromatography method development. J. Chromatogr. A. 1122, 186–193 (2006).
  Medline CASGoogle Scholar
• 10 Ye C, Liu J, Ren F, Okafo N. Design of experiment and data analysis by JMP^® (SAS Institute) in analytical method validation. J. Pharm. Biomed. Anal. 23, 581–589 (2000).
  Medline CASGoogle Scholar
• 11 Khamanga SM, Walker RB. The use of experimental design in the development of an HPLC–ECD method for the analysis of captopril. Talanta 83, 1037–1049 (2011).
  Medline CASGoogle Scholar
• 12 Dawes ML, Bergum JS, Schuster AE, Aubry A-F. Application of a design of experiment approach in the development of a sensitive bioanalytical assay in human plasma. J. Pharm. Biomed. Anal. 70, 401–407 (2012).
  Medline CASGoogle Scholar
• 13 Kormány R, Molnár I, Fekete J. Quality by design in pharmaceutical analysis using computer simulation with UHPLC. LCGC North America 32(5), 354–363 (2014).
  CASGoogle Scholar
• 14 Haber P, Baczek T, Kaliszan R, Snyder LR, Dolan JW, Wehr CT. Computer simulation for the simultaneous optimization of any two variables and any chromatographic procedure. J. Chromatogr. Sci. 38, 386–392 (2000).
  Medline CASGoogle Scholar
• 15 Galushko SV. Calculation of retention and selectivity in reversed-phase liquid chromatography J. Chromatogr. A. 552, 91–102 (1991).
  CASGoogle Scholar
• 16 Chambers EE, Fountain KJ, Smith N et al. Multidimensional LC–MS/MS enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma. Anal. Chem. 86(1), 694–702 (2014).
  Medline CASGoogle Scholar
• 17 FDA. Guidance for industry, safety testing of drug metabolites. February 2008. www.fda.gov.
  Google Scholar
• 18 ICH Guidance M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. June 2009. CPMP/ICH/286/95. www.emea.europa.eu.• Guidance under which laboratories must adhere to submit data to regulatory agencies.
  Google Scholar
• 19 Jemal M, Xia Y-Q. Bioanalytical method validation design for the simultaneous quantitation of analytes that may undergo interconversion during analysis. J. Pharm. Biomed. Anal. 22(5), 813–827 (2000).
  Medline CASGoogle Scholar
• 20 Jemal M, Ouyang Z, Powell ML. A strategy for a post-method validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples. Rapid Commun. Mass Spectrom. 16, 1538–1547 (2002).
  Medline CASGoogle Scholar
• 21 Voicu V, Gheorghe MC, Sora ID, Saarbu C, Medvedovici A. Incurred sample reanalysis: different evaluation approaches on data obtained for spironolactone and its active metabolite canrenone. Bioanalysis 3(12), 1343–1356 (2011).
  CASGoogle Scholar
• 22 Xue Y-J, Liu J, Simmons NJ, Unger S, Anderson DF, Jenkins RG. Separation of a BMS drug candidate and acyl glucuronide from seven glucuronide positional isomers in rat plasma via HPLC with MS/MS detection. Rapid Commun. Mass Spectrom. 20, 1776–1786 (2006).
  Medline CASGoogle Scholar
• 23 Su H, Boulton DW, Barros A Jr. et al. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metab. Dispos. 40(7), 1345–1356 (2012).
  Medline CASGoogle Scholar
• 24 Fast DM, Kelly M, Viswanathan CT et al. Workshop report and follow-up – AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples – implications of crystal city recommendations. AAPS J. 11, 238–241 (2009).
  MedlineGoogle Scholar
• 25 Meng M, Reuschel S, Bennett P. Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO. Bioanalysis 3(4), 449–465 (2011).
  CASGoogle Scholar
• 26 Poch GK, Unger S, Martinez N et al. Improved bioanalysis and pharmacokinetics by integrating radiolabeled metabolism data from a human clinical ADME study of [14C]-PAP prodrug. Presented at: 17th North American Regional ISSX International Society for the Study of Xenobiotics Meeting. Atlanta, GA, USA, 16–20 October 2011.
  Google Scholar
• 27 Li W, Zhang J, Tse FL. Strategies in quantitative LC–MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr. 25(1–2), 258–277 (2011).
  MedlineGoogle Scholar
• 28 Unger S, Lloyd T, Tan M, Hou J, Wells E. The science of laboratory and project management in regulated bioanalysis. Bioanalysis 6(10), 1357–1372 (2014).
  CASGoogle Scholar
• 29 Hughes NC, Bajaj N, Fan J, Wong EYK. Assessing the matrix effects of hemolyzed samples in bioanalysis. Bioanalysis 1, 1057–1066 (2009).
  CASGoogle Scholar
• 30 EMA. Guideline on bioanalytical method validation. July 2011. CHMP/EWP/192217/2009. www.ema.europa.eu/docs/en_GB/.• Guidance under which laboratories must adhere to submit data to regulatory agencies.
  Google Scholar
• 31 Viswanathan CT, Bansal S, Booth B et al. Workshop/conference report – quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 9, E30–E42 (2007).
  Google Scholar
• 32 Zou P, Yu Y, Zheng N et al. Applications of human pharmacokinetic prediction in first-in-human dose estimation. AAPS J. 14(2), 262–281 (2012).
  MedlineGoogle Scholar
• 33 Leung LY, Lim HK, Abell MW, Zimmerman JJ. Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. Ther. Drug Monit. 28(1), 51–61 (2006).
  Medline CASGoogle Scholar
• 34 King R, Bonfiglio R, Fernandez-Metzler C, Miller-Stein C, Olah T. Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. Mass Spectrom. 11, 942–950 (2000).
  Medline CASGoogle Scholar
• 35 Pulfer M, Murphy R. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 22, 332–364 (2003).
  Medline CASGoogle Scholar
• 36 Little J, Wempe M, Buchanan C. Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: examining lipid matrix ionization effects in plasma. J. Chromatogr. B. 833, 219–230 (2006).
  Medline CASGoogle Scholar
• 37 Matuszewski B, Constanzer M, Chavez-Eng C. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal. Chem. 75, 3019–3030 (2003).
  Medline CASGoogle Scholar
• 38 Matuszewski B. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC–MS bioanalysis. J. Chromatogr. B. 830, 293–300 (2006).
  Medline CASGoogle Scholar
• 39 Hall AB, Coy SL, Nazarov E, Vouros P. Development of rapid methodologies for the isolation and quantitation of drug metabolites by differential mobility spectrometry – mass spectrometry. Int. J. Ion Mobil. Spec. 2012 (15) 151–156 (2012).
  Google Scholar
• 40 Ray JA, Kushnir MM, Yost RA, Rockwood AL, Wayne Meikle A. Performance enhancement in the measurement of 5 endogenous steroids by LC–MS/MS combined with differential ion mobility spectrometry. Clin. Chim. Acta 438, 330–336 (2014).
  MedlineGoogle Scholar
• 41 Briggs RJ, Nicholson R, Vazvaei F et al. Method transfers, partial validation, and cross validation: recommendations for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 16(6), 1143–1148 (2014).
  Medline CASGoogle Scholar
• 42 Rozet E, Dewé W, Morello P et al. Risk-based approach for the transfer of quantitative methods: bioanalytical applications. J. Chromatogr. A. 1189(1–2), 32–41 (2008).
  Medline CASGoogle Scholar
• 43 FDA. Guidance for Industry: Bioanalytical Method Validation. www.fda.gov/downloads/Drugs.• Guidance under which laboratories must adhere to submit data to regulatory agencies.
  Google Scholar
• 44 Muirhead DC, Smart TS. Cross validation in bioanalysis: why, when and how? Chromatographia 52(1), S72–S75 (2000).
  CASGoogle Scholar
• 45 Xu X, Ji QC, Jemal M et al. Fit-for-purpose bioanalytical cross-validation for LC–MS/MS assays in clinical studies. Bioanalysis 5(1), 83–90 (2013).
  CASGoogle Scholar
• 46 Ji AJ, Jiang Z-P, Livson Y, Davis JA, Chu JX-G, Weng N. Challenges in urine bioanalytical assays: overcoming nonspecific binding. Bioanalysis 2(9), 1573–1586 (2010).
  CASGoogle Scholar
• 47 Bakhtiar R, Majumdar TK. Tracking problems and possible solutions in the quantitative determination of small molecule drugs and metabolites in biological fluids using liquid chromatography–mass spectrometry. J. Pharmacol. Toxicol. Meth. 55, 227–243 (2007).
  MedlineGoogle Scholar
• 48 Vallano PT, Shugarts SB, Woolf EJ, Matuszewski BK. Elimination of autosampler carryover in a bioanalytical HPLC–MS/MS method: a case study. J. Pharm. Biomed. Anal. 36(5), 1073–1078 (2005).
  Medline CASGoogle Scholar
• 49 Liu Y, Zheng B, Strafford S et al. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (−)ecgonine methyl ester in human acidified stabilized plasma samples. J. Chromatogr. B. 961, 77–85 (2014).
  Medline CASGoogle Scholar
• 50 Chang MS, Kim EJ, El-Shourbagy TA. A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection. Rapid Commun. Mass Spectrom. 20, 2190–2200 (2006).
  Medline CASGoogle Scholar
• 51 Loboda A, Krutchinsky A, Loboda O et al. Novel LINAC II electrode geometry for creating an axial field in a multipole ion guide. Eur. J. Mass Spectrom. 6(6), 531–536 (2000).
  CASGoogle Scholar
• 52 Heller D. Ruggedness testing of quantitative atmospheric pressure ionization mass spectrometry methods: the effect of co-injected matrix on matrix effects. Rapid Commun. Mass Spectrom. 21, 644–652 (2007).
  Medline CASGoogle Scholar
• 53 Jonsson O, Rodrigo P, Nilsson L et al. Capillary microsampling of 25µl blood for the determination of toxicokinetic parameters in regulatory studies in animals. Bioanalysis 4(6), 661–674 (2012).
  CASGoogle Scholar
• 54 Bowen C, Licea-Perez H, Karlinsey M et al. A novel approach to capillary plasma microsampling for quantitative bioanalysis. Bioanalysis 5(9), 1131–1135 (2013).
  CASGoogle Scholar
• 55 Barfield M, Spooner N, Lad R, Parry S, Fowles S. Application of dried blood spots combined with HPLC–MS/MS for the quantification of acetaminophen in toxicokinetic studies. J. Chromatogr. B. 870, 32–37 (2008).
  Medline CASGoogle Scholar
• 56 Lloyd T, Short J, Paul P. Exploration of automated sonication and direct elution approaches for the analysis of drugs in dried spots and other matrices. Presented at: Applied Pharmaceutical Analysis, Baltimore, MD, USA, 19–22 September 2010.
  Google Scholar
• 57 Zimmer J, Christianson C, Johnson C, Needham S. Recent advances in the bioanalytical applications of dried matrix spotting for the analysis of drugs and their metabolites. Bioanalysis 5(20), 2581–2588 (2013).
  CASGoogle Scholar
• 58 Lloyd T, Nunez S, Johnson R, Tan M. Full automation of dried blood spot LC/MS/MS methods for topiramate, warfarin, acetaminophen, ritonavir, lopinavir and saquinavir. Presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Antonio, TX, USA, 10–14 November 2013.
  Google Scholar
• 59 Thompson W, Zhang H, Smith P, Hillman S, Moseley A, Millington D. Extraction and analysis of carnitine and acylcarnitines by electrospray ionization tandem mass spectrometry directly from dried blood and plasma spots using a novel autosampler. Rapid Commun. Mass Spectrom. 26(21), 2548–2554 (2012).
  MedlineGoogle Scholar
• 60 Khadnevich L, Koster E. A new sample introduction technique for mass spectrometry that allows for dried blood spot analysis and online SPE. Presented at: European Bioanalysis Forum First Focus Meeting “Connecting Strategies on Dried Blood Spots.” Brussels, Belgium, 17–18 June 2010.
  Google Scholar
• 61 Heinig K, Wirz T, Bucheli F, Gajate-Perez A. Determination of oseltamivir (Tamiflu) and oseltamivir carboxylate in dried blood spots using offline or online extraction. Bioanalysis 3(4), 421–437 (2011).
  CASGoogle Scholar
• 62 Li F, Zulkoski J, Fast D, Michael S. Perforated dried blood spots: a novel format for accurate microsampling. Bioanalysis 3(4), 2321–2333 (2011).
  CASGoogle Scholar
• 63 Denniff P, Spooner N. Volumetric absorbtive micro sampling (VAMS): a novel dried sample collection technique for quantitative bioanalysis. Anal. Chem. 86(16), 8489–8495 (2014).
  Medline CASGoogle Scholar
• 64 Berman J, Halm K, Adkison K, Shaffer J. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J. Med. Chem. 40, 827–829 (1997).
  Medline CASGoogle Scholar
• 65 Zhu X, Sullivan MP, Orugunty R et al. Improving assay sensitivity with quaternary amine derivatives of bisphosphonates. Presented at: 60th ASMS Conference on Mass Spectrometry and Allied Topics Meeting, Vancouver, BC, Canada, 20–24 May 2012.
  Google Scholar
• 66 Shi G, Lloyd TL, Sy SKB et al. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. J. Pharm. Biomed. Appl. 31, 937–951 (2003).
  Medline CASGoogle Scholar
• 67 Brockman AH, Hatsis P, Paton M, Wu JT. Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. Anal. Chem. 79, 1599–1603 (2007).
  Medline CASGoogle Scholar
• 68 Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obes. Metab. 13, 7–18 (2011).
  Medline CASGoogle Scholar
• 69 Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829–835 (1993).
  Medline CASGoogle Scholar
• 70 Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952–957 (1995).
  Medline CASGoogle Scholar
• 71 Durinx C, Lambeir AM, Bosmans E et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 267, 5608–5613 (2000).
  Medline CASGoogle Scholar
• 72 Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88, 220–224 (2003).
  Medline CASGoogle Scholar
• 73 Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 142(2), 521–527 (2001).
  Medline CASGoogle Scholar
• 74 Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26, 2929–2940 (2003).
  Medline CASGoogle Scholar
• 75 Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 325, 175–182 (2008).
  Medline CASGoogle Scholar
• 76 Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur. J. Pharmacol. 589, 306–314 (2008).
  Medline CASGoogle Scholar
• 77 He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of [¹⁴C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab. Dispos. 37(3), 536–544 (2009).
  Medline CASGoogle Scholar
• 78 Xu XS, Demers R, Gu H et al. Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations. J. Chromatogr. B. 889-890, 77–86 (2012).
  Medline CASGoogle Scholar
• 79 Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods. 365(1–2), 38–49 (2011).
  Medline CASGoogle Scholar
• 80 Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49(4), 403–449 (1997).
  Medline CASGoogle Scholar
• 81 Van der Geest R, Kruger P, Gubbens-Stibbe JM, van Laar T, Bodde HE, Danhof M. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease, J. Chromatogr. B. 702, 131–141 (1997).
  Medline CASGoogle Scholar
• 82 Milstien S, Kaufman S. The oxidation of apomorphine and other catechol compounds by horseradish peroxidase: relevance to the measurement of dihydropteridine reductase activity. Biochim. Biophys. Acta 923(3), 333–338 (1987).
  Medline CASGoogle Scholar
• 83 Sam E, Augustijns P, Verbeke N. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. 658(2), 311–317 (1994).
  Medline CASGoogle Scholar
• 84 Kin NMK, Lal S, Thavundayil JX. Stability of apomorphine hydrochloride in aqueous sodium bisulphite solutions. Prog. Neuropsychophamacol. Biol. Psychiatry 25(7), 1461–1468 (2001).
  Medline CASGoogle Scholar
• 85 Barringer WC, Schultz W, Sieger GM, Nash RA. Minocycline hydrochloride and its relationship to the pharmaceutical properties of other tetracycline antibiotics. Am. J. Pharm. 146, 179–191 (1974).
  CASGoogle Scholar
• 86 Weng N, Roets E, Busson R, Hoogmartens J. Separation of keto-enol tautomers of chlortetracycline and 4-epichlortetracycline by liquid chromatography on poly(styrene divinylbenzene) copolymer. J. Pharm. Biomed. Anal. 8, 881–889 (1990).
  MedlineGoogle Scholar
• 87 Kahsay G, Shraim F, Villatte P et al. Development and validation of a reversed phase liquid chromatographic method for analysis of oxytetracycline and related impurities. J. Pharm. Biomed. Anal. 75, 199–206 (2013).
  Medline CASGoogle Scholar
• 88 Hoffman M, DeMaio W, Jordan RA et al. Metabolism, excretion, and pharmacokinetics of [14C] tigecycline, a first in class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab. Disp. 35(9), 1543–1553 (2007).
  MedlineGoogle Scholar
• 89 Sokoloski TD, Mitscher LA, Yuen PH, Juvarkar JV, Hoener B. Rate and proposed mechanism of anhydrotetracycline epimerization in acid solution. J. Pharm. Sci. 66(8), 1159–1165 (1977).
  Medline CASGoogle Scholar
• 90 Nelson M. The chemistry and cellular biology of the tetracyclines. In: Tetracyclines in Biology, Chemistry and Medicine. Nelson M, Hillen W, Greenwald RA (Eds). Birkhauser-Verlag, Boston, MA, USA, 23–24 (2001).
  Google Scholar
• 91 Nelis HJCF, De Leenheer AP. Metabolism of minocyclines in humans. Drug Metab. Disp. 10(2), 142–146 (1982).
  Medline CASGoogle Scholar
• 92 Jacobson J, Melander W, Vaisnys G, Horvath C. Kinetic study on cis-trans proline isomerization by high-performance liquid chromatography. J. Phys. Chem. 88(20), 4536–4542 (1984).
  CASGoogle Scholar
• 93 Patel DS, Sharma N, Patel MC et al. Analysis of a second-generation tetracycline antibiotic minocycline in human plasma by LC–MS/MS. Bioanalysis 3(19), 2177–2194 (2011).
  CASGoogle Scholar
• 94 Woolf EJ, McDougall S, Fast DM et al. Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Teams. AAPS J. 16(5), 885–893 (2014).
  Medline CASGoogle Scholar
• 95 Shi G. Application of co-eluting structural analog internal standards for expanded linear dynamic range in liquid chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 17, 202–206 (2003).
  Medline CASGoogle Scholar
• 96 Shaughnessy MJ, Harsanyi A, Li J, Bright T, Murphy CD, Sandford G. Targeted fluorination of a nonsteroidal anti-inflammatory drug to prolong metabolic half-life. ChemMedChem 9(4), 733–736 (2014).
  Medline CASGoogle Scholar
• 97 Orugunty RS, Sullivan M, Wells E, Unger S. pH dependent H/D exchange of 5-hydroxyindoleacetic acid-D5 and its impact on the performance as a stable labeled internal standard in bioanalytical methods. Presented at: 60th ASMS Conference on Mass Spectrometry and Allied Topics Meeting. Vancouver, BC, Canada, 20–24 May 2012.
  Google Scholar
• 98 Tan A, Levesque IA, Levesque IM, Viel F, Boudreau N, Levesque A. Analyte and internal standard cross signal contributions and their impact on quantitation in LC–MS based bioanalysis. J. Chromatogr. B. 879, 1954–1960 (2011).
  Medline CASGoogle Scholar
• 99 Sojo L, Lum G, Chee P. Internal standard signal suppression by co-eluting analyte in isotope dilution LC–ESI-MS. Analyst 128, 51–54 (2003).
  Medline CASGoogle Scholar
• 100 Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B. 852(102), 22–34 (2007).
  Medline CASGoogle Scholar
• 101 Wang S, Cyronak M, Yang E. Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma. J. Pharm. Biomed. Appl. 43, 701–707 (2007).
  Medline CASGoogle Scholar
• 102 Smeraglia J, Baldrey S, Watson D. Matrix effects and selectivity issues in LC–MS-MS. Chromatographia. 55, S95–S99 (2002).
  CASGoogle Scholar
• 103 Turowski M, Yamakawa N, Meller J et al. Deuterium isotope effects on hydrophobic interactions. The importance of dispersion interactions in the hydrophobic phase. J. Am. Chem. Soc. 125(45), 13836–13849 (2003).
  Medline CASGoogle Scholar
• 104 Tanaka N, Yamakawa N, Turowski M, Kimata K, Ikegami T, Hosoya K. Effect of stationary phase structure on the HPLC separation of hydrogen/deuterium isotopic compounds. Chromatographia 19(2), 82–83 (1998).
  Google Scholar
• 105 Iyer SS, Zhang Z-P, Kellogg GE, Karnes HT. Evaluation of deuterium isotope effects in normal-phase LC–MS–MS separations using a molecular modeling approach. J. Chromatogr. Sci. 42, 383–387 (2005).
  Google Scholar
• 106 Baweja R. Application of reversed-phase high-performance liquid chromatography for the separation of deuterium and hydrogen analogs of aromatic compounds. Anal. Chim. Acta 192, 345–348 (1987).
  CASGoogle Scholar
• 107 Jemal M, Schuster A, Whigan DB. Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: Method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. Rapid Commun. Mass Spectrom. 17(15), 1723–1734 (2003).
  Medline CASGoogle Scholar